Plain-English translation of NCT07372300 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing modulated electro-hyperthermia (mEHT)—a device that uses electromagnetic waves to safely heat tumor tissue to 39–42°C—in combination with standard chemotherapy and radiation for advanced rectal cancer. Researchers believe that combining this heat therapy with existing treatments may improve how well they work without causing extra side effects. About half of participants will receive the heat therapy along with standard care, while the other half will receive standard care alone.
Advanced rectal cancer currently requires aggressive chemotherapy, radiation, and surgery, but outcomes remain challenging. This trial explores whether adding targeted heat therapy to the tumor area during radiation and chemotherapy can improve treatment effectiveness and help more patients achieve better long-term results.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive 5–6 weeks of chemotherapy and radiation therapy. If you're in the treatment group, you'll also receive the heat therapy device twice per week during this period—each session lasts about an hour. After radiation ends, you'll continue with additional chemotherapy for 4–6 months, followed by surgery to remove the cancer. Throughout this time, you'll have regular appointments to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Taiwan